SAN FRANCISCO (EGMN) - The estimated 10-year risk for developing cardiovascular disease was at least as great as the risk of having a breast cancer recurrence in 78% of 242 postmenopausal women who were treated with an aromatase inhibitor for early-stage, hormone receptor-positive breast cancer.Clinicians should consider the effects of various breast cancer therapies on other potential health problems, such as cardiovascular disease, when choosing cancer treatment, Dr. Aditya Bardia said at a breast...